首页> 外文期刊>Pharmaceutical research >Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery
【24h】

Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery

机译:应用质量逐种设计方法优化脂质聚合物杂交纳米粒子,其装有剪接矫正反义寡核苷酸:最大化负荷和细胞内递送

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BackgroundAntisense oligonucleotides (ASOs) are promising therapeutics for specific modulation of cellular RNA function. However, ASO efficacy is compromised by inefficient intracellular delivery. Lipid-polymer hybrid nanoparticles (LPNs) are attractive mediators of intracellular ASO delivery due to favorable colloidal stability and sustained release properties.MethodsLPNs composed of cationic lipidoid 5 (L-5) and poly(DL-lactic-co-glycolic acid) were studied for delivery of an ASO mediating splice correction of a luciferase gene transcript (Luc-ASO). Specific purposes were: (i) to increase the mechanistic understanding of factors determining the loading of ASO in LPNs, and (ii) to optimise the LPNs and customise them for Luc-ASO delivery in HeLa pLuc/705 cells containing an aberrant luciferase gene by using a quality-by-design approach. Critical formulation variables were linked to critical quality attributes (CQAs) using risk assessment and design of experiments, followed by delineation of an optimal operating space (OOS).ResultsA series of CQAs were identified based on the quality target product profile. The L-5 content and L-5:Luc-ASO ratio (w/w) were determined as critical formulation variables, which were optimised systematically. The optimised Luc-ASO-loaded LPNs, defined from the OOS, displayed high loading and mediated splice correction at well-tolerated, lower doses as compared to those required for reference L-5-based lipoplexes, L-5-modified stable nucleic acid lipid nanoparticles or LPNs modified with dioleoyltrimethylammonium propane (conventional cationic lipid).ConclusionsThe optimal Luc-ASO-loaded LPNs represent a robust formulation that mediates efficient intracellular delivery of Luc-ASO. This opens new avenues for further development of LPNs as a broadly applicable technology platform for delivering nucleic acid cargos intracellularly.
机译:背景致密寡核苷酸(ASOS)是对细胞RNA功能的特异性调节的有前途的治疗方法。然而,ASO疗效因细胞内递送效率损害。脂质 - 聚合物杂交纳米颗粒(LPN)是由于良好的胶体稳定性和缓释性能,因此研究了由阳离子脂固醇5(L-5)和聚(DL-乳酸)组成的持续释放性能而具有细胞内ASO递送的介质。用于递送荧光素酶基因转录物(Luc-ASO)的ASO介导的接头校正。具体目的是:(i)提高确定LPN中ASO加载的因素的机制理解,(ii)优化LPN,并在含有异常荧光素酶基因的HELA Pluc / 705细胞中定制leu-aso递送。使用质量逐个方法。主要配方变量使用风险评估和实验设计与关键质量属性(CQAS)相关联,然后划定了最佳操作空间(OOS).Resultsa系列CQAS是根据质量目标产品简介识别的。 L-5含量和L-5:Luc-ASO比(W / W)被确定为临界配方变量,系统地优化。与基于参考L-5的脂肪量,L-5改性的稳定核酸的所需,优化的Luc-aso加载的LPN,从OOS定义,从OOS定义,以良好的耐受性,低剂量在耐受良好的较低剂量下显示出高负载和介导的接头校正用Dioleoyltrimethylampanium丙烷(常规阳离子脂质)改性的脂质纳米颗粒或LPN。最佳LUC-ASO加载的LPN,代表了培养的鲁克卡·索焦的有效细胞内递送的鲁棒配方。这开辟了新的途径,以进一步开发LPN,作为细胞内递送核酸尸体的广泛适用的技术平台。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号